BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Innovent and HUTCHMED’s Sintilimab-Fruquintinib Combo Accepted for NMPA Review in Advanced Renal Cell Carcinoma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

June 05, 2025 | News

Innovent Secures Second NMPA Breakthrough Therapy Designation for IBI363 in Advanced Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

June 05, 2025 | News

JW Therapeutics Secures Macao Approval for CAR-T Therapy Carteyva®, Marking First Overseas Market Entry

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunother...

June 05, 2025 | News

XellSmart Advances Global Leadership in iPSC-Derived Cell Therapies for CNS Disorders

XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell the...

June 03, 2025 | News

Concord Healthcare Unveils China’s First Proton Therapy-Focused Large Language Model

Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), whic...

June 02, 2025 | News

Mabwell Wins NMPA Approval for China’s First Albumin-Fused Long-Acting G-CSF Therapy MAILISHENG

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Albipagrastim alfa for Injection (trade name...

June 02, 2025 | News

Kexing Biopharm’s GB18 Receives IND Approval in China and U.S. for Cancer Cachexia Treatment

Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) applica...

May 30, 2025 | News

China Approves First Homegrown ADC, Trastuzumab Rezetecan, for HER2-Mutant Lung Cancer

The National Medical Products Administration has recently granted approval for Trastuzumab rezetecan, China's first domestically develo...

May 30, 2025 | News

AccurEdit’s ART001 Becomes First China-Developed Gene Editing Therapy to Receive FDA RMAT Designation

AccurEdit Therapeutics announced that its internally developed in vivo gene editing therapy ART001 has been granted a Regenerative Medi...

May 30, 2025 | News

Teddy Laboratory and LabConnect Forge Global Lab Alliance to Accelerate Drug Development

Teddy Laboratory, a subsidiary of Tigermed, officially signed a strategic cooperation agreement with LabConnect, LLC, a global leader in central labor...

May 30, 2025 | News

Eisai’s DAYVIGO® Approved in China to Treat Insomnia, Targeting Over 170 Million Adults

Eisai Co., Ltd. announced that the in-house-discovered and developed orexin receptor antagonist DAYVIGO® (generic name: lemborexant) has been app...

May 29, 2025 | News

RemeGen’s Telitacicept Approved in China as First Dual-Target Biologic for Generalized Myasthenia Gravis

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Produc...

May 28, 2025 | News

Zylox-Tonbridge Secures First Southeast Asia Approval for ZYLOX Unicorn™ Vascular Closure Device in Indonesia

Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge" or the "Company") announced that its proprietary ZYLOX Unicorn™ Vascular Closure Devi...

May 27, 2025 | News

Avenzo Therapeutics and Duality Biotherapeutics Gain FDA Clearance for EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418

Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-gen...

May 26, 2025 | News

Stay Connected